What is Amolyt Pharma?
Founded in 2014 and based in France, Amolyt Pharma is dedicated to developing novel peptide therapeutics for rare endocrine and metabolic diseases. The company's pipeline targets conditions with significant unmet medical needs, leveraging its expertise in peptide chemistry and drug development. Amolyt Pharma's strategic focus on rare diseases positions it within a critical segment of the biotechnology market, aiming to bring life-changing treatments to patients who currently have limited therapeutic options. The company's progression through various funding stages indicates a robust development trajectory and increasing market validation.
How much funding has Amolyt Pharma raised?
Amolyt Pharma has raised a total of $316.5M across 6 funding rounds:
Private Equity
$6.6M
Unspecified
$1.9M
Private Equity
$17.1M
Series A
$72.9M
Series B
$80M
Series C
$138M
Private Equity (2014): $6.6M with participation from Bpifrance and Octalfa
Unspecified (2015): $1.9M led by Sham Innovation Santu00e9, Octalfa, and Rhu00f4ne-Alpes Cru00e9ation
Private Equity (2016): $17.1M, investors not publicly disclosed
Series A (2019): $72.9M featuring Orbimed, Innobio 2, Novo Ventures, Pontifax, Kurma Partners, Partners Innovation Fund, Turenne Capital, TAB Consulting, Sham Innovation Santé, Crédit Agricole Création, and Life Sciences Partners
Series B (2021): $80M backed by Kurma Partners, Sectoral Asset Management, Novo Holdings, ATEM Capital, and Andera Partners
Series C (2023): $138M with participation from Tekla Healthcare Opportunities, ICG, Novo Holdings, CTI Life Sciences Fund, Kurma Partners, Sofinnova Partners, and Andera Partners
Key Investors in Amolyt Pharma
Tekla Healthcare Opportunities
Aberdeen Investments is a global specialist asset manager dedicated to providing investment solutions across various asset classes, catering to individual investors, financial advisors, and institutional clients. Their offerings include mutual funds, closed-end funds, exchange-traded funds (ETFs), and separately managed accounts, all supported by a network of over 500 financial professionals.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. The company was established in 1999 and is headquartered out of Hellerup, Denmark.
Kurma Partners
Kurma Partners is a prominent player in funding healthcare and biotechnology ventures across Europe. They specialize in investing at various maturity stages, from the inception of companies to capital expansion. With a strong network of partners, Kurma transforms disruptive scientific discoveries into advanced medical solutions, focusing on severe diseases with high unmet medical needs.
What's next for Amolyt Pharma?
With the recent influx of capital, Amolyt Pharma is poised to accelerate its clinical development programs and expand its research initiatives. The company's strategic investment is expected to fuel the progression of its lead candidates through clinical trials, potentially bringing them closer to regulatory approval and commercialization. This funding will also likely support the expansion of its scientific team and enhance its operational capabilities, reinforcing its position as a key player in the rare disease biotechnology landscape. Amolyt Pharma's continued growth trajectory suggests a future focused on delivering innovative solutions for complex endocrine and metabolic disorders.
See full Amolyt Pharma company page
